Sponsor content
175 result(s) found, displaying 21 to 30
-
Prescription medicine registrationActive ingredients: inebilizumab.
-
Prescription medicine registrationActive ingredients: blinatumomab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 5 mg / 1.0 mL (130 mg/26 mL) solution for intravenous infusion injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 90 mg/1.0 ml solution for subcutaneous injection pre-filled syringe.
-
Australian public assessment report (AusPar)Kyprolis (carfilzomib) was approved to treat relapsed or refractory multiple myeloma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 90 mg/1.0 ml solution for subcutaneous injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 5 mg / 1.0 mL (130 mg/26 mL) solution for intravenous infusion injection vial.